Pub Date : 2024-11-12eCollection Date: 2024-10-01DOI: 10.1183/20734735.0082-2024
Samuel R Wallbanks, Calvin Apen
Missing or inaccessible lung function measurements, gathered over time, have the potential to stagnate or impair clinical care decisions being made. This jeopardises patient safety and often contributes to excessive resource utilisation. Data integration is fundamental to clinical decision-making and entails amalgamating lung function data from multiple sources in a user-friendly format. Despite this, current systems for recording lung function data are suboptimal, with copious gaps in the clinical picture arising from missing or inaccessible lung function measurements. This article discusses the importance of data integration for lung function, with a call to action for key stakeholders involved in the performance, management and interpretation of such tests.
{"title":"Integration of lung function data: turning snapshots into stories.","authors":"Samuel R Wallbanks, Calvin Apen","doi":"10.1183/20734735.0082-2024","DOIUrl":"https://doi.org/10.1183/20734735.0082-2024","url":null,"abstract":"<p><p>Missing or inaccessible lung function measurements, gathered over time, have the potential to stagnate or impair clinical care decisions being made. This jeopardises patient safety and often contributes to excessive resource utilisation. Data integration is fundamental to clinical decision-making and entails amalgamating lung function data from multiple sources in a user-friendly format. Despite this, current systems for recording lung function data are suboptimal, with copious gaps in the clinical picture arising from missing or inaccessible lung function measurements. This article discusses the importance of data integration for lung function, with a call to action for key stakeholders involved in the performance, management and interpretation of such tests.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240082"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-12eCollection Date: 2024-10-01DOI: 10.1183/20734735.0104-2024
Simone Ielo, Andrea Campione, Nicola Leone, Cristiana Bellan, Raffaele Scala
Find out about some of the diagnostic considerations in the field of rare pleural disease https://bit.ly/3xYefzA.
了解罕见胸膜疾病领域的一些诊断注意事项 https://bit.ly/3xYefzA。
{"title":"Roadside serendipity: an accident can lead to a rare diagnosis.","authors":"Simone Ielo, Andrea Campione, Nicola Leone, Cristiana Bellan, Raffaele Scala","doi":"10.1183/20734735.0104-2024","DOIUrl":"https://doi.org/10.1183/20734735.0104-2024","url":null,"abstract":"<p><p><b>Find out about some of the diagnostic considerations in the field of rare pleural disease</b> https://bit.ly/3xYefzA.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240104"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chronic pulmonary aspergillosis has a range of manifestations from indolent nodules to semi-invasive infection. Patients may be asymptomatic or have chronic symptoms such as cough and weight loss or present with life-threatening haemoptysis. The physician can choose from a range of available therapies including medical therapy with antifungals, minimally invasive therapy with intracavitary antifungal therapy and surgery involving open thoracotomy or video-assisted thoracoscopic surgery. The patients with the most severe forms of pulmonary infection may not be surgical candidates due to their underlying pulmonary condition. The management of haemoptysis can include tranexamic acid, bronchial artery embolisation, antifungals or surgery. There are few controlled studies to inform clinicians managing complex cases, so a multidisciplinary approach may be helpful.
{"title":"Controversies in the clinical management of chronic pulmonary aspergillosis.","authors":"Xinxin Hu, Kathryn Hulme, Liana Brien, Sonya Natasha Hutabarat, Zinta Harrington","doi":"10.1183/20734735.0234-2023","DOIUrl":"10.1183/20734735.0234-2023","url":null,"abstract":"<p><p>Chronic pulmonary aspergillosis has a range of manifestations from indolent nodules to semi-invasive infection. Patients may be asymptomatic or have chronic symptoms such as cough and weight loss or present with life-threatening haemoptysis. The physician can choose from a range of available therapies including medical therapy with antifungals, minimally invasive therapy with intracavitary antifungal therapy and surgery involving open thoracotomy or video-assisted thoracoscopic surgery. The patients with the most severe forms of pulmonary infection may not be surgical candidates due to their underlying pulmonary condition. The management of haemoptysis can include tranexamic acid, bronchial artery embolisation, antifungals or surgery. There are few controlled studies to inform clinicians managing complex cases, so a multidisciplinary approach may be helpful.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"230234"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1183/20734735.0127-2023
Dávid László Tárnoki, Kinga Karlinger, Carole A Ridge, Fanni Júlia Kiss, Tamás Györke, Elzbieta Magdalena Grabczak, Ádám Domonkos Tárnoki
Imaging methods are fundamental tools to detect and diagnose lung diseases, monitor their treatment and detect possible complications. Each modality, starting from classical chest radiographs and computed tomography, as well as the ever more popular and easily available thoracic ultrasound, magnetic resonance imaging and nuclear medicine methods, and new techniques such as photon counting computed tomography, radiomics and application of artificial intelligence, has its strong and weak points, which we should be familiar with to properly choose between the methods and interpret their results. In this review, we present the indications, strengths and main limitations of methods for chest imaging.
{"title":"Lung imaging methods: indications, strengths and limitations.","authors":"Dávid László Tárnoki, Kinga Karlinger, Carole A Ridge, Fanni Júlia Kiss, Tamás Györke, Elzbieta Magdalena Grabczak, Ádám Domonkos Tárnoki","doi":"10.1183/20734735.0127-2023","DOIUrl":"10.1183/20734735.0127-2023","url":null,"abstract":"<p><p>Imaging methods are fundamental tools to detect and diagnose lung diseases, monitor their treatment and detect possible complications. Each modality, starting from classical chest radiographs and computed tomography, as well as the ever more popular and easily available thoracic ultrasound, magnetic resonance imaging and nuclear medicine methods, and new techniques such as photon counting computed tomography, radiomics and application of artificial intelligence, has its strong and weak points, which we should be familiar with to properly choose between the methods and interpret their results. In this review, we present the indications, strengths and main limitations of methods for chest imaging.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"230127"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1183/20734735.0043-2024
Helen O'Brien, John Murray, Nina Orfali, Ruairi J Fahy
Bone marrow transplantation, now often known as haematopoietic stem cell transplantation (HSCT), is a complex choreographed procedure used to treat both acquired and inherited disorders of the bone marrow. It has proven invaluable as therapy for haematological and immunological disorders, and more recently in the treatment of metabolic and enzyme disorders. As the number of performed transplants grows annually, and with patients enjoying improved survival, a knowledge of both early and late complications of HSCT is essential for respiratory trainees and physicians in practice. This article highlights the spectrum of respiratory complications, both infectious and non-infectious, the timeline of their likely occurrence, and the approaches used for diagnosis and treatment, keeping in mind that more than one entity may occur simultaneously. As respiratory issues are often a leading cause of short- and long-term morbidity, consideration of a combined haematology/respiratory clinic may prove useful in this patient population.
{"title":"Pulmonary complications of bone marrow transplantation.","authors":"Helen O'Brien, John Murray, Nina Orfali, Ruairi J Fahy","doi":"10.1183/20734735.0043-2024","DOIUrl":"10.1183/20734735.0043-2024","url":null,"abstract":"<p><p>Bone marrow transplantation, now often known as haematopoietic stem cell transplantation (HSCT), is a complex choreographed procedure used to treat both acquired and inherited disorders of the bone marrow. It has proven invaluable as therapy for haematological and immunological disorders, and more recently in the treatment of metabolic and enzyme disorders. As the number of performed transplants grows annually, and with patients enjoying improved survival, a knowledge of both early and late complications of HSCT is essential for respiratory trainees and physicians in practice. This article highlights the spectrum of respiratory complications, both infectious and non-infectious, the timeline of their likely occurrence, and the approaches used for diagnosis and treatment, keeping in mind that more than one entity may occur simultaneously. As respiratory issues are often a leading cause of short- and long-term morbidity, consideration of a combined haematology/respiratory clinic may prove useful in this patient population.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240043"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1183/20734735.0224-2023
Irma Mahmutovic Persson, Gracijela Bozovic, Gunilla Westergren-Thorsson, Sara Rolandsson Enes
For many severe lung diseases, non-invasive biomarkers from imaging could improve early detection of lung injury or disease onset, establish a diagnosis, or help follow-up disease progression and treatment strategies. Imaging of the thorax and lung is challenging due to its size, respiration movement, transferred cardiac pulsation, vast density range and gravitation sensitivity. However, there is extensive ongoing research in this fast-evolving field. Recent improvements in spatial imaging have allowed us to study the three-dimensional structure of the lung, providing both spatial architecture and transcriptomic information at single-cell resolution. This fast progression, however, comes with several challenges, including significant image file storage and network capacity issues, increased costs, data processing and analysis, the role of artificial intelligence and machine learning, and mechanisms to combine several modalities. In this review, we provide an overview of advances and current issues in the field of spatial lung imaging.
{"title":"Spatial lung imaging in clinical and translational settings.","authors":"Irma Mahmutovic Persson, Gracijela Bozovic, Gunilla Westergren-Thorsson, Sara Rolandsson Enes","doi":"10.1183/20734735.0224-2023","DOIUrl":"10.1183/20734735.0224-2023","url":null,"abstract":"<p><p>For many severe lung diseases, non-invasive biomarkers from imaging could improve early detection of lung injury or disease onset, establish a diagnosis, or help follow-up disease progression and treatment strategies. Imaging of the thorax and lung is challenging due to its size, respiration movement, transferred cardiac pulsation, vast density range and gravitation sensitivity. However, there is extensive ongoing research in this fast-evolving field. Recent improvements in spatial imaging have allowed us to study the three-dimensional structure of the lung, providing both spatial architecture and transcriptomic information at single-cell resolution. This fast progression, however, comes with several challenges, including significant image file storage and network capacity issues, increased costs, data processing and analysis, the role of artificial intelligence and machine learning, and mechanisms to combine several modalities. In this review, we provide an overview of advances and current issues in the field of spatial lung imaging.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"230224"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1183/20734735.0218-2023
Emer Kelly, Richard W Costello
The respiratory literature, both written and in online formats, is growing exponentially. Capturing quality content, to meet the learning needs of those working in all fields of respiratory medicine and delivering it in a palatable, accessible format is challenging but paramount. In this article we discuss ways to determine the information content and review different methods of delivering this content to those who need it.
{"title":"Large-scale education in respiratory medicine: content <i>versus</i> delivery.","authors":"Emer Kelly, Richard W Costello","doi":"10.1183/20734735.0218-2023","DOIUrl":"10.1183/20734735.0218-2023","url":null,"abstract":"<p><p>The respiratory literature, both written and in online formats, is growing exponentially. Capturing quality content, to meet the learning needs of those working in all fields of respiratory medicine and delivering it in a palatable, accessible format is challenging but paramount. In this article we discuss ways to determine the information content and review different methods of delivering this content to those who need it.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"230218"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1183/20734735.0081-2024
Sachin Ananth, Alexander G Mathioudakis, Jan Hansel
There is conflicting evidence regarding the use of steroids in severe community-acquired pneumonia (CAP), with previous randomised controlled trials limited by small sample sizes. ESCAPe and CAPE COD are two recently published large trials on steroids in severe CAP. ESCAPe assessed the initiation of methylprednisolone within 72-96 h of hospital admission, while CAPE COD studied the use of hydrocortisone within 24 h of the development of severe CAP. ESCAPe did not show any differences in all-cause 60-day mortality or any of its secondary outcomes. CAPE COD showed that hydrocortisone improved all-cause 28-day mortality and reduced the risk of intubation or vasopressor-dependent shock. Important differences between the trials included the steroid regimens used, timing of steroid administration and baseline characteristics, with more diabetic patients included in ESCAPe. The results of CAPE COD support the initiation of hydrocortisone within 24 h of developing severe CAP, but more research is needed to evaluate long-term outcomes and optimum dosing regimens for steroids in severe CAP.
关于类固醇在重症社区获得性肺炎(CAP)中的应用,目前存在相互矛盾的证据,以往的随机对照试验因样本量较小而受到限制。ESCAPe和CAPE COD是最近发表的两项关于类固醇治疗重症CAP的大型试验。ESCAPe对入院后72-96小时内开始使用甲基强的松龙进行了评估,而CAPE COD则对重症CAP发生后24小时内使用氢化可的松进行了研究。ESCAPe在全因60天死亡率或任何次要结果方面均未显示出任何差异。CAPE COD 显示,氢化可的松改善了 28 天内的全因死亡率,并降低了插管或血管加压休克的风险。两项试验之间的重要差异包括使用的类固醇方案、类固醇给药时间和基线特征,ESCAPe 纳入了更多的糖尿病患者。CAPE COD 的结果支持在发生严重 CAP 的 24 小时内开始使用氢化可的松,但还需要更多的研究来评估严重 CAP 的长期疗效和类固醇的最佳给药方案。
{"title":"Steroids in severe community-acquired pneumonia.","authors":"Sachin Ananth, Alexander G Mathioudakis, Jan Hansel","doi":"10.1183/20734735.0081-2024","DOIUrl":"10.1183/20734735.0081-2024","url":null,"abstract":"<p><p>There is conflicting evidence regarding the use of steroids in severe community-acquired pneumonia (CAP), with previous randomised controlled trials limited by small sample sizes. ESCAPe and CAPE COD are two recently published large trials on steroids in severe CAP. ESCAPe assessed the initiation of methylprednisolone within 72-96 h of hospital admission, while CAPE COD studied the use of hydrocortisone within 24 h of the development of severe CAP. ESCAPe did not show any differences in all-cause 60-day mortality or any of its secondary outcomes. CAPE COD showed that hydrocortisone improved all-cause 28-day mortality and reduced the risk of intubation or vasopressor-dependent shock. Important differences between the trials included the steroid regimens used, timing of steroid administration and baseline characteristics, with more diabetic patients included in ESCAPe. The results of CAPE COD support the initiation of hydrocortisone within 24 h of developing severe CAP, but more research is needed to evaluate long-term outcomes and optimum dosing regimens for steroids in severe CAP.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240081"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1183/20734735.0047-2024
Oke Dimas Asmara, Georgia Hardavella, Sara Ramella, René Horsleben Petersen, Ilona Tietzova, E Christiaan Boerma, Eric Daniel Tenda, Asmaa Bouterfas, Marjolein A Heuvelmans, Wouter H van Geffen
Stage III nonsmall cell lung cancer (NSCLC) represents a wide range of tumour (T1 to T4) and nodal (N0 to N3) components, requiring variable management and a multidisciplinary approach. Recent advancements in minimally invasive techniques, molecular biology and novel drug discoveries have accelerated the refinement of stage III NSCLC management. The latest developments in staging include the forthcoming update of the nodal component in the 9th TNM (tumour-node-metastasis) edition, which emphasises the critical role for endobronchial ultrasonography in mediastinal staging. Recent treatment developments include the use of immunotherapy and targeted molecular therapy in both the neoadjuvant and adjuvant setting, either in combination with other modalities or used alone as consolidation. Surgical and radiotherapy advancements have further enhanced patient outcomes. These developments have significantly improved the prognosis for patients with stage III NSCLC. Fast-changing recommendations have also brought about a challenge, with clinicians facing a number of options to choose from. Therefore, a multimodal approach by a multidisciplinary team has become even more crucial in managing stage III NSCLC.
III 期非小细胞肺癌(NSCLC)的肿瘤(T1 至 T4)和结节(N0 至 N3)成分范围很广,需要不同的管理和多学科方法。微创技术、分子生物学和新药发现的最新进展加速了对 III 期 NSCLC 管理的完善。分期方面的最新进展包括即将更新的第9版TNM(肿瘤-结节-转移)中的结节部分,其中强调了支气管内超声造影在纵隔分期中的关键作用。近期的治疗进展包括在新辅助治疗和辅助治疗中使用免疫疗法和靶向分子疗法,既可与其他方式联合使用,也可作为巩固治疗单独使用。手术和放疗的进步进一步提高了患者的治疗效果。这些进展大大改善了 III 期 NSCLC 患者的预后。快速变化的建议也带来了挑战,临床医生面临着多种选择。因此,多学科团队采用多模式方法治疗 III 期 NSCLC 变得更加重要。
{"title":"Stage III NSCLC treatment options: too many choices.","authors":"Oke Dimas Asmara, Georgia Hardavella, Sara Ramella, René Horsleben Petersen, Ilona Tietzova, E Christiaan Boerma, Eric Daniel Tenda, Asmaa Bouterfas, Marjolein A Heuvelmans, Wouter H van Geffen","doi":"10.1183/20734735.0047-2024","DOIUrl":"10.1183/20734735.0047-2024","url":null,"abstract":"<p><p>Stage III nonsmall cell lung cancer (NSCLC) represents a wide range of tumour (T1 to T4) and nodal (N0 to N3) components, requiring variable management and a multidisciplinary approach. Recent advancements in minimally invasive techniques, molecular biology and novel drug discoveries have accelerated the refinement of stage III NSCLC management. The latest developments in staging include the forthcoming update of the nodal component in the 9th TNM (tumour-node-metastasis) edition, which emphasises the critical role for endobronchial ultrasonography in mediastinal staging. Recent treatment developments include the use of immunotherapy and targeted molecular therapy in both the neoadjuvant and adjuvant setting, either in combination with other modalities or used alone as consolidation. Surgical and radiotherapy advancements have further enhanced patient outcomes. These developments have significantly improved the prognosis for patients with stage III NSCLC. Fast-changing recommendations have also brought about a challenge, with clinicians facing a number of options to choose from. Therefore, a multimodal approach by a multidisciplinary team has become even more crucial in managing stage III NSCLC.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240047"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-27eCollection Date: 2024-06-01DOI: 10.1183/20734735.0039-2024
Tuğbanur Tezvergil, Ismini Kourouni, Adrien E Costantini, Diego Kauffmann-Guerrero, Torsten Gerriet Blum, Thierry Berghmans
Stage IV nonsmall cell lung cancer (NSCLC) is a heterogeneous group of patients for whom systemic therapy is decided based on tumour-biological cancer features (histology, PD-L1 expression, genomic alteration, metastatic sites) and patient characteristics (performance status, comorbidities). In most instances, some kind of systemic treatment is proposed, for which immunotherapy-based or targeted therapies are considered the standards of care in 2024. Oligometastatic NSCLC represents a specific concept during the biological spectrum from localised to metastatic disease in which only a limited number of metastatic sites can be documented. Based on this assumption, prospective and a few randomised phase II studies have been performed, which suggested that adding a local ablative treatment to the systemic one can be a new option for selected stage IV NSCLC. The European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO) supported efforts to define oligometastatic NSCLC to unify the semantics within the thoracic oncology community. This article summarises the currently available data and emphasises the questions and perspectives in oligometastatic disease NSCLC in European patient cohorts.
{"title":"Stage IV nonsmall cell lung cancer treatment: oligometastatic disease and disease progression, untangling the knot.","authors":"Tuğbanur Tezvergil, Ismini Kourouni, Adrien E Costantini, Diego Kauffmann-Guerrero, Torsten Gerriet Blum, Thierry Berghmans","doi":"10.1183/20734735.0039-2024","DOIUrl":"10.1183/20734735.0039-2024","url":null,"abstract":"<p><p>Stage IV nonsmall cell lung cancer (NSCLC) is a heterogeneous group of patients for whom systemic therapy is decided based on tumour-biological cancer features (histology, PD-L1 expression, genomic alteration, metastatic sites) and patient characteristics (performance status, comorbidities). In most instances, some kind of systemic treatment is proposed, for which immunotherapy-based or targeted therapies are considered the standards of care in 2024. Oligometastatic NSCLC represents a specific concept during the biological spectrum from localised to metastatic disease in which only a limited number of metastatic sites can be documented. Based on this assumption, prospective and a few randomised phase II studies have been performed, which suggested that adding a local ablative treatment to the systemic one can be a new option for selected stage IV NSCLC. The European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO) supported efforts to define oligometastatic NSCLC to unify the semantics within the thoracic oncology community. This article summarises the currently available data and emphasises the questions and perspectives in oligometastatic disease NSCLC in European patient cohorts.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"240039"},"PeriodicalIF":2.3,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}